Jan 15, 2020
The Malignant Pleural Mesothelioma Market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy, which have shown promising anticancer activity against mesothelioma in recent clinical trials. These drugs have been approved for other indications and now are being used in mono...
Read More...
Jan 13, 2020
Malignant pleural mesothelioma (MPM) is a malignancy of pleural layers within the lung cavity and inner sides of the ribs. Year of research has revealed asbestos exposure as the primary cause of the malignancy. The longer the asbestos exposure, more is the risk of a person developing mesothelioma. It...
Read More...
DAWNZERA’s EU Approval Strengthens the Hereditary Angioedema Treatment Landscape
Jan 30, 2026
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
The Dynamic Landscape of Myelofibrosis Treatment: A 2024 Perspective
Jun 10, 2024
Newsletter/Whitepaper